Brokerage Reports
Protalix BioTherapeutics, Inc. [PLX]
Reports for Purchase
Showing records 41 - 60 ( 77 total )
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AIR DNase Demonstrates Potential; Raising Price Target
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fabry Competitor Falters; Potentially Higher Brazil Sales; Raising Price Target to $4 per Share
Provider: Rodman & Renshaw, Co.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fabry Competitor Falters; Potentially Higher Brazil Sales; Raising Price Target to $4 per Share
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Phase 3 Fabry Disease Trial Patient Dosing Begins; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Phase 3 Fabry Disease Trial Patient Dosing Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Financial Results Reported; Clinical Catalysts Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Financial Results Reported; Clinical Catalysts Ahead; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protalix Enters Phase 2 in Cystic Fibrosis; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protalix Enters Phase 2 in Cystic Fibrosis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector
Provider: H.C. Wainwright & Co., Inc.
Price: 100.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12- month price target of $3.50 per share.
Provider: Rodman & Renshaw, Co.
Price: 75.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12- month price target of $3.50 per share.
Provider: H.C. Wainwright & Co., Inc.
Price: 75.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Similar to Last Year, Enterprise & Client Solid State Drives Remain Primary Focus at the 2012 Flash Memory Summit; Increasing SanDisk PT to $39
Provider: WEDBUSH SECURITIES INC.
Analyst: VAN HEES B
Price: 25.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reiterate Buy and $9 PT; Q1 Uneventful; Eyes on Elelyso launch in US
Provider: AURIGA USA
Analyst: YANG D
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrade to Buy and raise PT to $9.00; Elelyso Approval Validates the Technology Platform
Provider: AURIGA USA
Analyst: YANG D
Price: 25.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrade to Hold and Maintain $8 PT; Uncomfortable betting on May 1 PDUFA Binary Event
Provider: AURIGA USA
Analyst: YANG D
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiate on a Biotech Company with Innovative Manufacturing Process; BUY, $8 PT
Provider: AURIGA USA
Analyst: YANG D
Price: 50.00
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage of Biotechnology Stocks
Provider: CAPSTONE INVESTMENTS
Price: 10.00